

# Testimonial – Vaccine Antigen



Novexin has developed a novel, proprietary technology that is radically improving the processing of proteins. Our technology provides a simple method that eliminates the need to screen multiple conditions whilst reducing yield losses due to aggregation and allowing higher protein concentrations to be analysed. It's generic use allows a Yes/No answer to be reached quickly on refolding success and the technology is scalable for low cost processing.

## Introduction

Microscience, now Emergent Europe, is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical need. Primarily they are involved in the research and development of innovative, proprietary vaccines and immunotherapeutics in the areas of typhoid, travellers' diarrhoea, hepatitis B, anthrax, neonatal group B and meningitis.

## Summary

"We (Microscience) found using Novexin's refolding technology in kit format extremely straightforward and easy to use whilst the results it generated were excellent.

We found that using Novexin's kit we were able to obtain a single species of protein with no loss of yield compared to the heterogeneous mixture of species we obtained when using our routine refolding conditions.

We will definitely use Novexin's kits again for further work with this protein and will incorporate the technology in our refolding studies with future proteins"

## Results

